Chennai, Aug 20: India’s clinical contract research industry, with current market size of $500 million is poised to double over five years and achieve billion dollar market club. As a leading Indian Contract Research Organisation (CRO), Accutest Biologics Private Limited (ABPL) is all set to leverage the growing global demand for biologics and biosimilar drugs.
The leading CRO for biochemical characterization and bioanalytical services, in support of preclinical and clinical development of biologics and biosimilars, ABPL has recently received a global honour with the OECD-Good Laboratory Practice (GLP) certification for the next three years. National Good Laboratory Practice Compliance Monitoring Authority (NGCMA) had conducted a detailed pre-inspection of the test facility located at Navi Mumbai and this year in May, received the GLP certification.
Founder and CEO, ABPL, Dr Satish Sawant said, “The Navi Mumbai facility is capable of conducting toxicity studies, mutagenicity studies, analytical and clinical testing. This significant milestone enables us to advance as the global service provider living up to the biopharmaceutical industry expectations and maintaining high-quality deliverables.”